Immunotherapy for Solid Tumors

Hortense de Saint Basile¹, Zineb Maaradji¹, Elizabeth Fabre^{1

2}

Affiliations

¹ APHP, Paris Cancer Institute CARPEM, Department of Thoracic Oncology, European Hospital Georges Pompidou, 75015 Paris, France.
² INSERM Team UMR_S970, Immunotherapy and Antiangiogenic Treatment in Cancerology, Paris Descartes University, 75015 Paris, France.

Editorial

Hortense de Saint Basile et al. Cancers (Basel). 2023.

. 2023 Mar 8;15(6):1646.

doi: 10.3390/cancers15061646.

Hortense de Saint Basile¹, Zineb Maaradji¹, Elizabeth Fabre^{1

2}

¹ APHP, Paris Cancer Institute CARPEM, Department of Thoracic Oncology, European Hospital Georges Pompidou, 75015 Paris, France.
² INSERM Team UMR_S970, Immunotherapy and Antiangiogenic Treatment in Cancerology, Paris Descartes University, 75015 Paris, France.

Abstract

The development of immune checkpoint inhibitors (ICIs) constitutes a major therapeutic advance in the treatment of a number of malignancies [...].

The authors declare no conflict of interest.

1. Yuan G., Flores N.M., Hausmann S., Lofgren S.M., Kharchenko V., Angulo-Ibanez M., Sengupta D., Lu X., Czaban I., Azhibek D., et al. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature. 2021;590:504–508. doi: 10.1038/s41586-020-03170-y. - DOI - PMC - PubMed
1. Xu D., Liu S., Wu X., Marti T.M., Dorn P., Schmid R.A., Peng R.-W., Shu Y. Dissecting the immunological profiles in NSD3-amplified LUSC through integrative multi-scale analyses. Cancers. 2022;14:4997. doi: 10.3390/cancers14204997. - DOI - PMC - PubMed
1. Walter P., Ron D. The unfolded protein response: From stress pathway to homeostatic regulation. Science. 2011;334:1081–1086. doi: 10.1126/science.1209038. - DOI - PubMed
1. Guezour N., Soussi G., Brosseau S., Abbar B., Naltet C., Vauchier C., Poté N., Hachon L., Namour C., Khalil A., et al. Grade 3–4 immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients are correlated with better outcome: A real-life observational study. Cancers. 2022;14:3878. doi: 10.3390/cancers14163878. - DOI - PMC - PubMed
1. Evdokimova V., Gassmann H., Radvanyi L., Burdach S.E.G. Current state of immunotherapy and mechanisms of immune evasion in ewing sarcoma and osteosarcoma. Cancers. 2022;15:272. doi: 10.3390/cancers15010272. - DOI - PMC - PubMed